

Technology Appraisal Committee A Interests Register

Topic: ID6325 Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677)

Publication Date: 05 November 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Zoe Phillips	TAC Committee Member	Indirect – Financial Interests	Zoe has received income (via salary) by working as a consultant for one of the comparator companies (Jazz) but on a different indication and compound.	22/05/2025	It was agreed that Zoe's declaration would not prevent her from participating in discussions on this appraisal.
Dominic Pivonka	TAC Committee Member	Indirect – Financial Interests	Dominic's employer (AbbVie) has a treatment with positive phase 3 results for mantle cell lymphoma	26/05/2025	It was agreed that Dominic's declaration would prevent him from participating in discussions on this appraisal.
Hugo Pedder	TAC Committee Member	Indirect – Financial Interests	Hugo has received payment for work on behalf of Baxter Healthcare in the last 12 months for a technology and indication unrelated to this.	03/06/2025	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.
Dr Sunil Iyengar	Clinical Expert	Direct – financial	• Received payments for speaking engagements and advisory from	01/07/2025	It was agreed that Dr Sunil Iyengar's declaration would not prevent him

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Gilead. I have a private practice at the Royal Marsden hospital.</p> <ul style="list-style-type: none"> Co-authored the real-world data publication on the UK experience with Brexucabtagene autoleucel: Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis <p>Jun 2024HEMASPHERE8(6):12 pages WILEY</p> <p>O'Reilly MA, Wilson W, Burns D, Kuhn A, Seymour F, Uttenthal B, Besley C, Alajangi R, Creasey T, Paneesha S, Elliot J, Arias CG, Iyengar S, Wilson MR, Delaney A, Rubio L, Lambert J, Begg K, Boyle S, Cheek KPL, Collins GP, Roddie C, Johnson R, Sanderson R</p>		from providing expert advice to the committee.
Professor Andrew Davies	Clinical Expert	Direct – financial	<ul style="list-style-type: none"> received payment to deliver two symposiums on CAR-T therapy [Jan 2025] and participated as a reviewer of scientific research proposals for Kite/Gilead fellowship scheme I was 	01/07/2025	It was agreed that Professor Andrew Davies' declaration would not prevent him from providing

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			renumerated to an approximate total £3000 across the above. • My host NHS organisation (University Hospitals Southampton) has received research funding for the conduct of clinical trials sponsored by Kite/Gilead but not in this indication		expert advice to the committee.
		Direct – non-financial	• Member of the European Haematology Association and British Society of Haematology Diffuse large B-cell lymphoma Guidelines writing group. I chair the national lymphoma research group. This does not cover the scope of this appraisal.		
		Indirect	• received honoraria for speaking and support to attend medical conferences from Roche, the makers of originator rituximab. This is often included in the management of mantle cell lymphoma with chemotherapy and has been considered a comparator. My financial support from Roche is approximately £10,000). In the NHS biosimilar rituximab is used almost		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			exclusively and not the Roche product. My work with Roche does not have any connection with rituximab and is not in the field of mantle cell lymphoma. Other Roche products are not comparators in this appraisal. Allogeneic transplantation does not include the use rituximab.		